BoneSupport Names Mr. Offer Nonhoff As New Chief Financial Officer

LUND, Sweden, July 2, 2012 /PRNewswire/ -- BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced the appointment of Mr. Offer Nonhoff as Chief Financial Officer. Mr. Nonhoff replaces Mr. Fredrik Groth who is leaving the Company to pursue new challenges. Mr. Nonhoff comes to BONESUPPORT from Lumenis, a global leader in the medical laser industry, where he served as Vice President Finance and Sales Operations for the EMEA region for the past three years.

In his role, Mr. Nonhoff will define the process and implement infrastructure systems needed to support a substantial growth phase, including financial, accounting, legal and information technology systems. As a member of the senior management team, Mr. Nonhoff will report to the CEO, and in addition to his finance role participate in strategic planning related to the Company's geographical expansion into new markets.

"For the past six months, we have been building the foundation for a period of disciplined, focused and profitable growth based upon a well-defined strategy and business plan," said Lloyd Diamond, CEO of BONESUPPORT. "After much thought and consideration, we found Mr. Nonhoff's deep knowledge of international corporate finance and experience in the German market, combined with his industry experience at both large established companies and start-up organizations, make him a key asset and we are happy to welcome him to the team."

Mr. Diamond further added, "We also want to thank Mr. Groth for his extensive experience and strong commitment to the Company, which has helped to bring BONESUPPORT to commercialization. We wish him success in his new endeavors."

Mr. Nonhoff is a seasoned global finance executive with more than twenty years of experience and a proven track record. Prior to serving as Vice President Finance and Sales Operations for Lumenis, Mr. Nonhoff worked for Animation Lab, a high tech media start up company. Before that, he spent fifteen years at Siemens, one of the worlds largest medical and electronic engineering companies. During his tenure as CFO Siemens Israel, he led Siemens to win and execute many large tenders, which enabled the Company to achieve market leadership in several fields of business.

Mr. Diamond added, "Mr. Nonhoff's record of success is impressive. His focus and drive make him an extremely valuable asset which will serve BONESUPPORT well during our planned expansion into new markets and new product offerings."

"BONESUPPORT is implementing a major strategic transformation, moving from research and development to a commercialization phase," said Mr. Nonhoff. "I am thrilled to be joining the team at such an exciting time, and I look forward to contributing my experience to help BONESUPPORT achieve its goals."

Born and raised in Berlin, Mr. Nonhoff studied in Germany and the U.S., receiving a BA of Industrial Business Administration from the IHK in Munich.

For more information about BONESUPPORT and CERAMENT, visit www.BONESUPPORT.com.

About BONESUPPORT

BONESUPPORT is an emerging leader of injectable bone substitutes for orthopedic trauma focusing on bone infection, instrument augmentation related to orthopedic surgery and spinal applications. CERAMENT is a fully developed product platform that is commercially available in the U.S. and Europe and is revolutionizing the treatment of fragility and other fractures caused by disease and trauma. Scientific research of CERAMENT spans more than eleven years and over forty-five pre-clinical, clinical and animal studies have been conducted. More than 4,000 patients have been treated with CERAMENT. The company was founded in 1999 and is based in Lund, Sweden with subsidiary locations in the US and Germany. To learn more about BONESUPPORT please visitwww.bonesupport.com.

Press Inquiries:

Lloyd Diamond
Chief Executive Officer
Phone: +46 46 286 53 61
Lloyd.Diamond@bonesupport.com

SOURCE BONESUPPORT

Back to news